AR and neoplasm: Genomic interrogation of castration-resistant prostate cancer (CRPC) tumours has provided a catalogue of mutations and copy number alterations that are associated with disease spread and evolution during androgen receptor (AR)-targeted androgen deprivation therapy (ADT)1, 2, 3, 4, 5.